Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key NSCLC data updates discussed following the 2023 ASCO Annual Meeting.
Choosing Appropriate Patients for Dual Immunotherapy/Chemotherapy in NSCLC
September 18th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed which patients with non–small cell lung cancer should receive immunotherapy-containing regimens. This is the second of 2 articles based on this event.
Read More
Significant Benefit Shown with Perioperative Durvalumab/Chemo in Resectable NSCLC
September 16th 2023According to research led by Tetsuya Mitsudomi, MD, perioperative durvalumab plus chemotherapy may be better than placebo plus chemotherapy for the treatment of resectable non–small cell lung cancer.
Read More
2 Clarke Drive
Cranbury, NJ 08512